Tumor necroptosis is correlated with a favorable immune cell signature and programmed death-ligand 1 expression in cholangiocarcinoma

被引:0
|
作者
Thanpisit Lomphithak
Perawatt Akara-amornthum
Keigo Murakami
Masatoshi Hashimoto
Hajime Usubuchi
Erina Iwabuchi
Michiaki Unno
Zhenyu Cai
Hironobu Sasano
Siriporn Jitkaew
机构
[1] Chulalongkorn University,Graduate Program in Clinical Biochemistry and Molecular Medicine, Department of Clinical Chemistry, Faculty of Allied Health Sciences
[2] Tohoku University School of Medicine,Department of Pathology
[3] Tohoku University School of Medicine,Department of Surgery
[4] Tongji University,Tongji University Cancer Center, Shanghai Tenth People’s Hospital, School of Medicine
[5] Chulalongkorn University,Age
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Necroptosis, a regulated form of necrosis, has emerged as a novel therapeutic strategy that could enhance cancer immunotherapy. However, its role in tumorigenesis is still debated because recent studies have reported both anti- and pro-tumoral effects. Here, we aimed to systematically evaluate the associations between tumor necroptosis (mixed lineage kinase domain-like protein, MLKL; phosphorylated MLKL, pMLKL; and receptor-interacting protein kinase 1–receptor-interacting protein kinase 3, RIPK1–RIPK3 interaction) and tumor-infiltrating immune cells (CD8+ and FOXp3+ T cells and CD163+ M2 macrophages) and tumor PD-L1 by immunohistochemistry in 88 cholangiocarcinoma (CCA) patients who had undergone surgical resection. Their associations with clinicopathological characteristics, survival data, and prognosis were evaluated. MLKL was found to be an unfavorable prognostic factor (p-value = 0.023, HR = 2.070) and was inversely correlated with a clinically favorable immune cell signature (high CD8+/high FOXp3+/low CD163+). Both pMLKL and RIPK1–RIPK3 interaction were detected in CCA primary tissues. In contrast to MLKL, pMLKL status was significantly positively correlated with a favorable immune signature (high CD8+/high FOXp3+/low CD163+) and PD-L1 expression. Patients with high pMLKL-positive staining were significantly associated with an increased abundance of CD8+ T cell intratumoral infiltration (p-value = 0.006). Patients with high pMLKL and PD-L1 expressions had a longer overall survival (OS). The results from in vitro experiments showed that necroptosis activation in an RMCCA-1 human CCA cell line selectively promoted proinflammatory cytokine and chemokine expression. Jurkat T cells stimulated with necroptotic RMCCA-1-derived conditioned medium promoted PD-L1 expression in RMCCA-1. Our findings demonstrated the differential associations of necroptosis activation (pMLKL) and MLKL with a clinically favorable immune signature and survival rates and highlighted a novel therapeutic possibility for combining a necroptosis-based therapeutic approach with immune checkpoint inhibitors for more efficient treatment of CCA patients.
引用
收藏
相关论文
共 50 条
  • [31] Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
    Chen, Kaiyan
    Cheng, Guoping
    Zhang, Fanrong
    Zhang, Nan
    Li, Dan
    Jin, Jiaoyue
    Wu, Junzhou
    Ying, Lisha
    Mao, Weimin
    Su, Dan
    ONCOTARGET, 2016, 7 (21) : 30772 - 30780
  • [32] The prognostic significance of programmed cell death-ligand 1 expression in pulmonary squamous cell carcinoma
    Hung, Jung-Jyh
    Wu, Yu-Chung
    Hsu, Wen-Hu
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
  • [33] Temporal and Spatial Heterogeneity of Programmed Cell Death-Ligand 1 Expression in Malignant Mesothelioma
    Terra, Simone B. S. P.
    Mansfield, Aaron S.
    Peikert, Tobias
    Roden, Anja C.
    LABORATORY INVESTIGATION, 2017, 97 : 496A - 497A
  • [34] Temporal and Spatial Heterogeneity of Programmed Cell Death-Ligand 1 Expression in Malignant Mesothelioma
    Terra, Siinone B. S. P.
    Mansfield, Aaron S.
    Peikert, Tobias
    Roden, Anja C.
    MODERN PATHOLOGY, 2017, 30 : 496A - 497A
  • [35] Temporal Heterogeneity of Programmed Cell Death-Ligand 1 Expression in Thymic Epithelial Tumors
    Terra, Simone
    Mansfield, Aaron S.
    Roden, Anja
    MODERN PATHOLOGY, 2018, 31 : 753 - 753
  • [36] PROGRAMMED CELL DEATH-LIGAND 1 OVEREXPRESSION IN THYROID CANCER
    Zhang, Guo-Qiang
    Wei, Wei-Jun
    Song, Hong-Jun
    Sun, Zhen-Kui
    Shen, Chen-Tian
    Zhang, Xin-Yun
    Chen, Xiao-Yue
    Qiu, Zhong-Ling
    Luo, Quan-Yong
    ENDOCRINE PRACTICE, 2019, 25 (03) : 279 - 286
  • [37] Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy
    Vivar, Karina L.
    Deschaine, Maria
    Messina, Jane
    Divine, Jennifer M.
    Rabionet, Alejandro
    Patel, Nishit
    Harrington, Michael A.
    Seminario-Vidal, Lucia
    JOURNAL OF CUTANEOUS PATHOLOGY, 2017, 44 (04) : 381 - 384
  • [38] Temporal Heterogeneity of Programmed Cell Death-Ligand 1 Expression in Thymic Epithelial Tumors
    Terra, Simone
    Mansfield, Aaron S.
    Roden, Anja
    LABORATORY INVESTIGATION, 2018, 98 : 753 - 753
  • [39] Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas
    Zeng, Jing
    Zhang, Xin-Ke
    Chen, Hua-Dong
    Zhong, Zhi-Hai
    Wu, Qiu-Liang
    Lin, Su-Xia
    ONCOTARGET, 2016, 7 (08) : 8944 - 8955
  • [40] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway
    Wang, Tianyu
    Wu, Xiaoxing
    Guo, Changying
    Zhang, Kuojun
    Xu, Jinyi
    Li, Zheng
    Jiang, Sheng
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (04) : 1715 - 1730